Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 4,924,000 | 4,901,000 | 5,249,000 | 4,972,000 | 4,994,000 |
| Cost of Goods | 2,331,000 | 2,311,000 | 2,464,000 | 2,371,000 | 2,337,000 |
| Gross Profit | 2,593,000 | 2,590,000 | 2,785,000 | 2,601,000 | 2,657,000 |
| Operating Expenses | 3,075,000 | 1,658,000 | 1,196,000 | 2,661,000 | 1,650,000 |
| Operating Income | -482,000 | 932,000 | 1,589,000 | -60,000 | 1,007,000 |
| Other Income | -196,000 | -253,000 | -1,419,000 | -81,000 | -109,000 |
| Pre-tax Income | -678,000 | 679,000 | 170,000 | -141,000 | 898,000 |
| Income Tax | -222,000 | 53,000 | -110,000 | -57,000 | 39,000 |
| Net Income Continuous | -456,000 | 626,000 | 280,000 | -84,000 | 859,000 |
| Minority Interests | -4,000 | -4,000 | -40,000 | -5,000 | -4,000 |
| Net Income | $-452,000 | $630,000 | $320,000 | $-79,000 | $863,000 |
| EPS Basic Total Ops | -0.53 | 0.74 | 0.37 | -0.09 | 0.99 |
| EPS Basic Continuous Ops | -0.54 | 0.73 | 0.33 | -0.10 | 0.99 |
| EPS Diluted Total Ops | -0.53 | 0.74 | 0.38 | -0.09 | 0.99 |
| EPS Diluted Continuous Ops | -0.54 | 0.73 | 0.33 | -0.10 | 0.98 |
| EBITDA(a) | $-82,000 | $1,319,000 | $1,982,000 | $352,000 | $1,391,000 |